Skip Navigation

European Heart Journal 1989 10(3):235-243;
Copyright © 1989 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by WAINWRIGHT, C. L.
Right arrow Articles by BIGAUD, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WAINWRIGHT, C. L.
Right arrow Articles by BIGAUD, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1989 The European Society of Cardiology

The effects of PAF antagonists on arrhythmias and platelets during acute myocardial ischaemia and reperfusion

C. L. WAINWRIGHT, J. R. PARRATT and M. BIGAUD*

Department of Physiology and Pharmacology, University of Strathclyde Glasgow Scotland U.K.

Received 10 October 1988; .

Address for Correspondence: Dr C L Wainwright, Department of Physiology and Pharmacology, University of Strathclyde, 204 George Street, Glasgow G1 1XW, Scotland, U.K.

Abstract

The aim of the study was to examine a possible role for platelet activating factor (PAF) in experimental myocardial ischaemia and reperfusion. Anaesthetized open-chest greyhounds were subjected to 40 min of coronary artery (LAD) occlusion followed by reperfusion. Blood samples for platelet counting were obtained from a local coronary vein draining the ischaemic region. Pretreatment with PAF antagonists BN52021 (5 mg kg-1 i.v.) or SRI63 441 (10mg kg-1 i.v.), 15 min prior to occlusion reduced the ventricular ectopic count during the ischaemic period from 614 ± 82 (controls) to 296 ± 145 (BN52021) and 474 ± 200 (SRI 63 441). Both drugs also reduced the incidence of ventricular fibrillation (VF) (during ischaemia and reperfusion) from 90% (controls), to 50% (BN52021) and 43% (SRI63441). Ischaemia was accompanied by a 32 ± 7% reduction in coronary venous platelets; this was attenuated by both BN52021 (–2 ± 6%) and SRI 63 441) (–1± 5%). These results suggest that PAF may contribute to ischaemia and reperfusion-induced arrhythmias by activating platelets.

Key Words: Myocardial ischaemia • Reperfusion • Arrhythmias • Platelets • PAF • antagonists


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.